Mild parkinsonism in persons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)

J W Tetrud; J W Langston; P L Garbe; A J Ruttenber

doi:10.1212/wnl.39.11.1483

Mild parkinsonism in persons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)

Neurology. 1989 Nov;39(11):1483-7. doi: 10.1212/wnl.39.11.1483.

Authors

J W Tetrud¹, J W Langston, P L Garbe, A J Ruttenber

Affiliation

¹ California Parkinson's Foundation, San Jose 95128.

PMID: 2812327
DOI: 10.1212/wnl.39.11.1483

Abstract

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) produces moderate to severe parkinsonism in humans, but has not been reported to cause a syndrome similar to early Parkinson's disease. We now report 22 cases of mild parkinsonism resulting from exposure to MPTP.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / adverse effects*
Adult
Disability Evaluation
Humans
Injections, Intravenous
Middle Aged
Narcotics
Nervous System / physiopathology
Neurologic Examination
Parkinson Disease, Secondary / chemically induced*
Parkinson Disease, Secondary / physiopathology
Parkinson Disease, Secondary / psychology
Substance-Related Disorders / physiopathology
Substance-Related Disorders / psychology

Substances

Narcotics
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine